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1. Introduction 
Health related problems affect every human being in an interconnected way, between 
generations and between societies, through spatial and temporal transitions. This timeless 
and all-pervasive aspect of health makes biotechnology unique among all technologies. 
While the science that drives biotechnology has far to go before it reaches a comparable level 
of maturity of eighteenth century physics, nevertheless biology is now deeply rooted in 
science; it has taken huge strides from its humble beginnings as a classification science to 
cell biology, to molecular biology, and now modestly to quantum biology. Erwin 
Schrödinger, a pioneer of quantum mechanics, was among the first scientists to suggest, in 
his book What is Life? (Schrödinger, 1944), that quantum mechanics can provide deep 
insights into life’s mechanisms. However, our current understanding of how such quantum 
phenomena as superposition, entanglement, collapse of the wavefunction, etc. affect the 
chemistry of life is nascent (Ball, 2011). 
The links in the supply chain that support biotechnology products and services include 
knowledge creation in R&D laboratories, product creation in biotechnology and 
pharmaceutical industries, and the ultimate receiver of therapeutic remedies—a human 
patient, inter alia, communally bound by morality and ethics. The fact that this supply chain, 
in principle, must cater to every human being on our planet, demands that it be protected 
with utmost care. Perhaps the most vulnerable link in this chain is the patentable knowledge 
created through privately funded R&D, which, unless diligently protected, is easy prey to 
infringement and theft. The maintenance of this chain is astronomically expensive and 
complex as it must balance some extreme needs: huge funding for exploration-intensive, 
curiosity-driven, ‘blue-sky’ R&D; highly risky upfront investments by industry before going 
to market; enormous funds to protect its intellectual property, if necessary, through 
litigation; and the need to provide safe and affordable remedies to very large populations of 
indigent people in the world to keep them healthy. 
This chapter is written for biotechnologists who wish to get an understanding of the role 
patents could play in protecting and advancing their research output in the service of 
mankind when commercial applications of that research is the optimal means of doing so. 
Here we discuss general principles of biotechnology patents and related issues, rather than 
country specific ones.  
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2. The promise of biotechnology 
Biotechnology took roots more than 10,000 years ago. The ‘old or traditional’ methods of 
biotechnology were mainly fermentation (through the unwitting use of microbes) to 
produce such products as beer, wine, and cheese, and cross-breeding (through the 
unwitting use of genetic material) to modify plants and animals through progressive 
selection for desired traits. These methods were developed empirically, patiently, and 
over countless years (Darwin, 1872; Smith 2009). It was only during 1857 and 1876 that the 
fermentative ability of microorganisms was demonstrated by Louis Pasteur (Smith, 2009). 
The discovery by Alexander Fleming of the antibiotic penicillin in 1929 and its large-scale 
production in the 1940s created major advances in fermentation technology. Since then the 
technology has advanced rapidly not just in the production of antibiotics but in many 
other biochemical products including organic acids, polysaccharides, enzymes, vaccines, 
and hormones. Modern breeding methods now selectively move genes within the same 
species or between species. 
The ‘new or modern’ biotechnology that emerged in the 1970s is (Lilly, 1997) “the 
application of scientific and engineering principles to the processing of materials by 
biological agents to provide goods and services.” Its methods use microbial, animal or plant 
cells or enzymes for the purposes of breaking down, synthesizing, or transforming 
materials. The scientific foundation of biotechnology was laid in a remarkable paper by 
James D. Watson and Francis H. C. Crick in Nature (Watson & Crick, 1953), which elucidated 
the double-helix structure of cellular DNA1 (deoxyribonucleic acid). It gave birth to 
molecular biology and paved the way for developing recombinant DNA and cell fusion 
techniques along with scientific versions of ‘old’ biotechnological processes of modern 
biotechnology. Advances such as the transformation of Escherichia coli2; cutting and joining 
DNA strands (recombinant DNA technology) (Cohen, et al, 1973)3; the rapid cloning of 
DNA strands (PCR technique) (Mullis, et al, 1986); the ability to make monoclonal 
antibodies (hybridoma technique) (Köhler & Milstein, 1975)4, etc. have made possible the 
creation of genetically engineered life forms capable of manufacturing new and improved 
drugs, such as, human insulin, interferons, vaccines, and treatments for a host of human 
afflictions such as septic shock, anemia, diabetes, AIDS, cancer, hepatitis, and heart attack. 
Genetically engineered transgenic animals such as the Harvard mouse5 and the SCID 
mouse6 play an immensely important role in cancer and immunology research, respectively. 
Many other transgenic life forms such as bacteria, cows, pigs, goats, etc. play a crucial role in 
                                                 
1 Formally known as B-DNA. Other forms of DNA, e.g., A-DNA, C-DNA, D-DNA, Z-DNA, DNA-
triplex, DNA-quadruplex, etc. also exist. B-DNA is the most stable helical form adopted by random 
sequence DNA under physiological conditions 
2 This bacterium was discovered by Theodor Escherich (and named after him) in 1885.  
3 The method was protected by three patents, which have now expired.  
4 Amazingly, the method was never patented.  
5 In 1988, Philip Leder and Timothy Stewart of Harvard University inserted a cancer gene into mouse 
egg cells and produced the patented transgenic mouse (U.S. Patent No. 4,736,866, now expired). 
Transgenic mice have become an incredibly powerful cancer research tool.  
6 The SCID (severe combined immunodeficiency) mouse lacks T and B lymphocytes and immuno-
globulins, either from inbreeding with an autosomal-recessive trait or from genetic engineering. It is 
used as a model for studies of the immune system.   
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the development of therapies and the manufacture of pharmaceuticals. Thus one of the main 
objectives of biotechnology is to find means of scaling-up biological processes.  
The mapping of the human genome independently by the Human Genome Project and by 
Celera Genomics in 2001 was a remarkable breakthrough in data collection to aid studies of 
the human body.7 A crucial step in providing personalized medical care was thus taken. The 
breakthrough creation of a bacterial cell controlled by a chemically synthesized genome was 
reported by Craig Ventor’s team in May 2010 in Science (Gibson, et al, 2010). The team reported 
synthesizing the genome of the bacterium Mycoplasma mycoides, comprising some 1.1 million 
base pairs as a proof of principle that cells can be produced based upon genome sequences 
designed in the computer. There is, of course, much to be learnt before one can construct and 
transplant whole computer-designed genomes of higher life forms. Important limiting factors 
are insufficient scientific knowledge of gene structure and function, and of microRNAs.   
The potential curative abilities of stem cells come from their remarkable ability to renew 
themselves through cell division, sometimes even after long periods of inactivity, and to 
develop into many different cell types in the body. When a stem cell divides, each new cell, 
under appropriate circumstances, may either remain a stem cell or become a specialized cell 
such as a muscle cell, a red blood cell, or a brain cell. This unique regenerative ability of 
stem cells offers new opportunities for treating diseases such as diabetes and heart disease. 
However, much remains to be understood about them before reliable cell-based therapies 
can be designed to treat diseases.  
The strength of modern biotechnology comes from its interdisciplinary nature and the 
interactions it orchestrates between various parts of biology and engineering. It draws 
insights and knowledge from a wide range of fields: biochemistry, microbiology, molecular 
biology, cell biology, immunology, protein engineering, enzymology, breeding techniques, 
chemical engineering, mechanical engineering, computational methods, mathematical 
simulation, bioinformatics, etc. The products and processes it spawns are the results of 
intense R&D, astronomical funding, and the unique entrepreneurial spirit of the 
biotechnology community in converting R&D results into therapies and cures, diagnostic 
tools and tests for disease detection, etc.  
At present, biotechnology produces a range of embryonic enabling technologies for which 
some applications are known and many more expected. It is sustained by an enormous faith 
that suites of these enabling technologies, when further refined and augmented, will 
eventually find vast new applications of tremendous value to society. So the main benefits 
essentially lie in the future. The expected benefits include novel personalized 
pharmaceutical drugs and therapies for many diseases based on individual genomic 
information, genetically engineered healthier food with longer shelf-life, and new energy-
efficient techniques for protecting the environment. The biotechnology industry’s 
                                                 
7 The first analyses of the working draft human genome sequence were reported in the February 16, 
2001 issue of Science and February 15, 2001 issue of Nature. The papers from Nature included initial 
sequence analyses generated by the publicly sponsored Human Genome Project, while Science 
publications focused on the draft sequence reported by the private company, Celera Genomics. The 
papers can be found at  
http://www.ornl.gov/sci/techresources/Human_Genome/project/journals/journals.shtml.  
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dependence on multi-nation patent protection for survival in the marketplace is therefore 
not at all surprising. In fact, it is imperative that every biotechnology researcher 
understands the circumstances when acquiring and protecting his research results by 
patents is crucial. Breakthrough R&D results by themselves are not enough; to serve society 
they must lead to commercially viable products and processes or find philanthropic hosts or 
find federal support. Of particular research interest are genes and their corresponding 
proteins as they are believed to represent the future of diagnostic and therapeutic medicine. 
3. Basics of patent law  
A patent is a limited period monopoly intellectual property right granted to an inventor of 
any country by a Government of any other or same country for an invention that fulfills 
prescribed statutory requirements of the granting country. Patent monopoly differs from 
market monopoly; a patent is a right to exclude, a right to prevent trespassing. In this sense 
it is no different from, say, the right to keep our house or car or any other personal 
possession free from trespassers. A patent grants inventors the right to exclude others from 
making, using, selling or offering to sell, and importing the claimed invention in the country 
of grant; it does not confer any right to practice the invention. This is because in practicing 
the invention, one may well need complementary patents held by others unwilling to 
cooperate or there may be other laws, rules or regulations that prevent its practice.  
Patents are issued only to the first inventor (or group of joint inventors) of an invention who 
files a legally valid patent application; all others are barred, even if they independently 
created the invention. Consequently, those other inventors must get a license from the first 
inventor if they wish to practice the invention. Patents granted by a country, like its laws, 
have no extraterritorial effect; hence patents are unenforceable, if infringed, in another 
country where the invention in question is not patented. If multi-country patent protection 
is required, the invention must be patented in each desired country. There is no such thing 
as a “world-wide patent”. 
The modern concept of patents dates back to the year 1421, when the Italian city-state 
Florence granted the first recorded patent to Fillippo Brunelleschi, for the design and use of 
a ship, the Badalone (seagoing monster; it was used to carry marble along the Arno river), 
for three years.8 The Venetian Senate passed the first patent law on March 14, 1474, granting 
limited duration monopoly for original devices. That same Venice in 1594 granted Galileo9 a 
“privilege” (what we know as a patent) on a machine which he had invented10 “for raising 
water and irrigating land with small expense and great convenience,” on the condition that 
it had never before been thought of or made by others. In his petition for the privilege he 
                                                 
8 Christine MacLeod, Inventing the Industrial Revolution: The English Patent System. 1660-1800, 
Cambridge University Press, 2002, p. 11. 
9 Galileo Galilei (February 18, 1564 – January 8, 1642) is known as the father of modern science. He is 
perhaps the only scientist who is known by his first name rather than his last. In life sciences, Leonardo 
da Vinci, who preceded Galileo, is actually the unacknowledged “father of modern science” because of 
his remarkable studies of the human anatomy, and his empirical approach to science. See, e.g., Fritjof 
Capra, The Science of Leonardo, Doubleday, New York, 2007. 
9 Inkster, I., Potentially Global: A Story of Useful and Reliable Knowledge and Material Progress in 
Europe circa 1474-1912. Available at  
http://www.lse.ac.uk/collections/economicHistory/GEHN/GEHNPDF/PotentiallyGlobal-IInkster.pdf.   
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said, “it not being fit that this invention, which is my own, discovered by me with great 
labor and expense, be made the common property of everyone,” adding further, that if he 
were granted the privilege, “I shall the more attentively apply myself to new inventions for 
universal benefit.” Clearly, even the great scientist Galileo was not willing to divulge his 
invention for free exploitation by others without just compensation for his efforts. The 
Venetian Council granted Galileo a “privilege” for 21 years.  
An invention is the creation of a new technical idea and of the physical means to accomplish 
or embody it. An idea per se is not an invention; a useful and successful implementation of 
an idea is. Four types of inventions are eligible for patents: process, machine, manufacture, 
or composition of matter, collectively known as statutory subject matter. They are subject to 
certain limitations that vary from country to country. However, there is universal agreement 
among nations that abstract ideas (e.g., mathematical formulas), laws of nature, natural 
phenomena, and products of nature are ineligible, but their application to a known structure 
or process may be eligible. What to exclude from patent monopoly is a national prerogative, 
largely derived from government policy decisions that accrue from the prevailing socio-
economic conditions it must manage, and international treaty obligations. 
Inventions that qualify as statutory subject matter must then face additional stringent statutory 
tests of substantial and credible utility (industrial application) in the eyes of an expert (such as 
a patent examiner in a patent office) in the field of the invention, novelty with respect to prior 
art (state-of-the-art) as it exists on the date of filing the patent application (in the United States 
there is some relaxation available), and nonobviousness, i.e., the invention has an inventive 
step that is unlikely to have been made by a person having ordinary skill in the art 
(PHOSITA), if required, assuming he would make the effort to study relevant prior art.   
There is a quid pro quo attached to the grant of patents. To get a patent the inventor must put 
the invention in the public’s possession. He must therefore fully describe his invention 
(written description requirement) in the patent application before the invention is formally 
examined by a patent examiner (examination typically takes two or more years). This 
description must be so clear and detailed as to enable a person skilled in the technologies 
related to the invention in question (an expert) to independently reproduce the invention 
(enablement requirement) without undue extra-solution activity, such as further research, 
data gathering, etc. on his part. In fact, this description should leave no doubt that the patent 
applicant was in possession of the claimed invention at the time of filing his application. 
Patents may be granted on improvements over existing inventions.  
Patent laws of a country do not over-ride its other laws that might regulate the invention’s 
use. For example, a new pharmaceutical cannot be marketed without the approval of 
appropriate authorities. Patent laws of a country may take into account moral, cultural, 
ethical, social, environmental, or scientific concerns of society.  
In most countries with a patent regime, a pending patent application is placed in the 
public’s possession 18 months after the first “priority” filing date11 of the application or the 
                                                 
11 The priority date of a patent application is the filing date of the first patent application (the priority 
document), which discloses the invention, and to which priority is properly claimed in the country of 
interest. The written description of the invention in the priority document should be detailed enough so 
as to enable one skilled in the relevant art to make and use the invention. 
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date of patent grant, whichever is earlier, by means of publication in print and world-wide-
web enabled media. This gives an opportunity to others to improve upon the invention and 
possibly patent improvements (or focus on something else), without unduly stifling 
innovation. Limited period monopoly (usually 20 years from the priority filing date) is 
meant to prevent undue concentration of economic power, yet allow inventors (a rare breed) 
an opportunity to recover costs and earn profit from their long and expensive effort, not 
otherwise possible if others could reverse engineer the invention (often a far less expensive 
process) and duplicate it without penalty. The goal has been to get as many useful 
inventions into the public domain and in free use as soon as possible and thus enrich society 
as a whole without being unfair to the inventor. Patent protection is therefore a bargain 
struck by society on the premise that, in its absence there would be insufficient invention 
and innovation. Patent and other laws do not forbid an altruistic inventor (unless bound by 
a legal contract, say, to his employer) from freely placing his patentable inventions in the 
public domain without patent protection.  
Patents are granted to inventors. The rights attached to a patent may be exercised by the 
patentee, his or her heirs or assigns during the term of the patent. A patent may be assigned 
(e.g., to one’s employer) or licensed, with or without conditions attached, to one or more 
legal entities. A patent license to a licensee is an agreement that the patent owner will not 
enforce certain or all rights of exclusion against the licensee. Anyone else infringing the 
patent can be sued in a court of law by the patent’s owner. 
Limited period patent monopoly may provide an enormous first mover advantage to an 
entrepreneur, especially if it involves new technology. Alexander Graham Bell’s two 
telephone patents—“Improvement in Telegraphy” (U.S. 174,465), granted on March 7, 
1876, provided a monopoly on the basic principle of telephony, and “Improvement in 
Electric Telegraphy” (U.S. 186,787) granted on January 30, 1877, provided a monopoly on 
the telephone hardware—are outstanding examples. By the time the patents expired, 
American Bell (later to become AT&T) had acquired a “natural monopoly” in the 
telephone business. 
An alternative to patent protection is to keep the invention a trade secret, which lasts as long 
as the secret is kept. This works if the invention’s independent discovery is so unlikely that 
it can be monopolized indefinitely. Otherwise, independent discoverers of the secret can 
practice their invention with impunity, and worse, one of them may patent it and deny all 
others the use of the invention if not licensed from him. If one is keen to commercialize the 
invention, patent protection is much safer than trade secret, especially during negotiations 
with investors when detailed exposure of the invention may be necessary. At times, keeping 
marginal improvements of a patented invention as trade secrets may be preferred, especially 
if constrained by patenting costs. 
3.1 Filing and prosecuting a patent application  
To get a patent one must file a patent application at an appropriate office designated for the 
purpose, usually the patent office of the selected country. Each country has its own rules 
and regulations for filing and these must be strictly followed. To claim priority over others 
for an invention, it is necessary to be the “first to file” the application in accordance with the 
country’s statutory requirements, which may include statutory grace periods. To claim 
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priority, one may file a provisional application which, at the minimum, fulfills the written 
description and enablement requirements, but it must be followed, within a year, by a 
proper application for the same invention as described in the provisional application, else 
the priority date is lost. Patent offices act only on proper applications. Provisional 
applications remain dormant during their life. 
Prosecution is the process by which a (proper) patent application is defended before a 
patent office. The process often lasts several years. The application includes a complete 
description of the invention, a list of claims on statutory subject matter sought to be 
protected, and the requisite filled-in patent office forms, along with a filing fee. As 
prosecution proceeds, there may be other fees to be paid at various stages. For filing and 
prosecution details, visit the website of the desired patent office. 
3.2 Patent claims 
The legal core of a patent application is the list of claims. Each claim in this list covers and 
secures a process, a machine, a manufacture, a composition of matter, or a design, but never 
the function or result of either, nor the scientific explanation of their operation. The claims 
define the scope of a patent grant and function to forbid not only exact copies of an invention 
but also products that go to the heart of the invention but avoid the literal language of the 
claim by making a non-critical change. (See Section 4 below.) Whether a claim is allowed by a 
patent office is judged on the basis of novelty, nonobviousness, and utility (industrial 
applicability) of the invention being considered. Of course, claims are interpreted in light of 
the description of the invention provided in the patent application and information elicited 
during prosecution from the inventor, prior art and other sources. Almost all litigation related 
to patent infringement centers on the validity and scope of the claims.  
In biotechnology, claims may be product claims, process claims, or product-by-process 
claims. Product claims may include such things as novel protein products, known but 
purified protein products, DNA sequence of a gene that encodes a particular protein, etc. 
Process claims may include preparation or use of recombinant DNA, the use of bacteria or 
cultured cells transformed with vectors containing DNA encoding a desired protein 
product, methods of use for proteins, methods for production or use of monoclonal 
antibodies, etc. Product-by-process claims deal with products that are too complex to be 
described conventionally (e.g., with reference to its composition, structure or some other 
testable parameter) and hence are described by the process with which it is made. By such 
claims it is not possible to use a new process to claim an old product. The focus here is the 
patentability of the product itself, not on the process used to describe it since the reference to 
a process serves only the purpose of defining the product.  
There have been attempts by biotechnology inventors to get “reach-through claims” 
granted. Such claims seek to protect things which may not have been identified by the 
applicant in his patent application but which may be identified in the future by others by 
carrying out the invented process. This is different from the product-by-process claims as 
the products claimed in reach-through claims are speculative and hence do not fulfill the 
statutory requirements of disclosure and enablement. The purported justification for such 
broad extra-legal claims is that a pioneering invention paves the way for subsequent 
inventions and hence its inventor is “entitled” to capture some of the follow-on value based 
on the relative contribution of his pioneering invention. (Christie & Lim, 2005; IPO, 2009) 
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4. Infringement  
Protecting an active patent when infringed can be a nightmare. It is time consuming, and 
hugely expensive (usually measured in millions of U.S. dollars) if it involves litigation. 
Alleged infringers, if challenged, are quite likely to counter-challenge by questioning the 
validity of the disputed patent. It is therefore imperative, especially in biotechnology where 
patents underpin business, that patent applications are prepared by experienced patent 
attorneys and that inventors work closely with them to minimize litigation possibilities. 
Considerations that go into the preparation of a fortified patent application include the 
doctrine of equivalent, prosecution history estoppel, reverse doctrine of equivalents, prior 
art or state-of-the-art, and the anticipated profile of the imaginary PHOSITA.  
4.1 Doctrine of equivalents 
Literal infringement of a valid active patent where the alleged infringer exactly or nearly 
exactly copies an invention without a licence from the patent owner is understandably rare. 
Generally, one tries to work around a patented invention by introducing differences and 
variations to avoid infringement. The question then is whether the modified product or 
process is remote enough from the patent that it will not infringe. Inadvertent infringement 
may arise if a product or process is invented in ignorance of an active patent whose 
existence is discovered only later, say, after a business commitment has been made to 
produce the product or use the process.  
Such situations are partially dealt with by the judicially created doctrine of equivalents. This 
is a rule of claim interpretation under which a product or process, although not a literal 
infringement, is an infringement if it performs substantially the same function in 
substantially the same way to obtain the same result as a patented product or process. This 
doctrine, which has universal appeal, expands patent protection beyond the literal language 
of the claim. To determine what counts as an equivalent one must find a balance between 
two opposing public policies: (1) the importance of providing public notice as to what 
infringes by requiring clear and distinct claims, and (2) the need to prevent an infringer 
from avoiding liability by merely playing semantic games or by making only minor changes 
in the accused product or process to avoid the literal language of the claims (Belvis, 2003). In 
litigation, courts may seek expert opinion as to scientific or engineering facts and the 
decision may well depend on the most believable expert. Note that things that are 
equivalent for one purpose may not be so for other purposes. The Supreme Court of the 
United States sums it succinctly in Graver Tank12:  
What constitutes equivalency must be determined against the context of the patent, the 
prior art, and the particular circumstances of the case. Equivalence, in the patent law, is 
not the prisoner of a formula and is not an absolute to be considered in a vacuum. It 
does not require complete identity for every purpose and in every respect. In 
determining equivalents, things equal to the same thing may not be equal to each other 
and, by the same token, things for most purposes different may sometimes be 
equivalents. Consideration must be given to the purpose for which an ingredient is 
used in a patent, the qualities it has when combined with the other ingredients, and the 
                                                 
12 Graver Tank & Mfg. Co. v. Linde Air Products, 339 U.S. 605 (1950). Available at  
http://supreme.justia.com/us/339/605/case.html.  
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function which it is intended to perform. An important factor is whether persons 
reasonably skilled in the art would have known of the interchangeability of an 
ingredient not contained in the patent with one that was. 
In Warner-Jenkinson13 the same Court then clarified and restricted the application of the 
doctrine of equivalents, holding that: 
Each element contained in a patent claim is deemed material to defining the scope of 
the patented invention, and thus the doctrine of equivalents must be applied to individual 
elements of the claim, not to the invention as a whole. It is important to ensure that the 
application of the doctrine, even as to an individual element, is not allowed such broad 
play as to effectively eliminate that element in its entirety. [Emphasis added] 
This restriction on the doctrine of equivalents serves to eliminate one of the great mischiefs 
that could be played in patent law. Absent this rule, one could attempt to use the doctrine of 
equivalents to subvert patent claims. Rather than focusing on specific claim language and 
elements of the claim, the case could be tried based on how the accused device was 
equivalent to that claim as a whole. The Court further held that the equivalence 
determination was to be made at the time of the alleged infringement and not at the time the 
patent issued. It is likely that the less certain and more complex the courts perceive a 
scientific field underlying a technology to be (as is the case with biotechnology), the less 
scope will be given to patents under the doctrine of equivalents. If the patent is a pioneer in 
a whole new field, it will generally receive a broader range of equivalents than one for a 
narrow improvement to existing technology (Blenko, 1990). There are a few other 
restrictions that circumscribe the doctrine of equivalents: prosecution history estoppel, the 
reverse doctrine of equivalents, and prior art. 
4.2 Prosecution history estoppel 
During prosecution, quite likely, one or more claims will be rejected or require amendment 
to become narrower and detailed, in view of prior art. If a claim is allowed after being 
narrowed to avoid prior art, the patentee is barred from asserting the narrowed claim in its 
earlier broader sense under the doctrine of equivalents. This means that broad claims that 
have to be amended during prosecution can be difficult to enforce, if infringed. In short, 
rejected or narrowed claims cannot be expanded to their earlier scope under the doctrine of 
equivalents. In fact, such claims practically forego any benefit that could have accrued under 
the doctrine of equivalents in infringement cases.  
4.3 Reverse doctrine of equivalents 
A further restriction on the doctrine of equivalents is the reverse doctrine of equivalents.  As 
noted by the Supreme Court of the United States in the Graver Tank case: 
The wholesome realism of this doctrine [of equivalence] is not always applied in favor 
of a patentee but is sometimes used against him. Thus, where a device is so far changed 
                                                 
13 Warner-Jenkinson Co. v. Hilton Davis Chemical Co., 520 U.S. 17 (1997). Available at  
http://supreme.justia.com/us/520/17/case.html.   
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in principle from a patented article that it performs the same or similar function in a 
substantially different way, but nevertheless falls within the literal words of the claim, 
the doctrine of equivalents may be used to restrict the claim and defeat the patentee’s 
action for infringement. [Citations omitted]  
Thus, where an invention relies on the fundamental concept embodied in a patent but is 
more sophisticated than the patented device due to “a significant advance,” the accused 
device does not infringe by virtue of the reverse doctrine of equivalents. Once a patentee 
establishes literal infringement, the burden is on the alleged infringer to establish non-
infringement under the reverse doctrine of equivalents. This is an untested area of patent 
law but may become important in biotechnology with respect to certain pioneering 
technologies, such as, synthetic cell technology. 
4.4 Prior art 
Prior art or state-of-the-art is all information, available in any form, in the public domain. It 
does not include secret information, such as trade secrets. The existing reservoir of ideas and 
their expression form the foundation on which new intellectual property is built. Normally, 
prior art does not include unpublished work or mere conversations (although in the 
European Patent Convention, oral disclosures do form prior art14). There is a continuing 
effort by various countries to document their respective traditional knowledge, such as 
medicinal properties of plants, and make that knowledge available as searchable prior art. 
The doctrine of equivalents excludes whatever is already prior art. 
4.5 The PHOSITA in biotechnology 
In examining a patent application, the patent examiner faces an immediate problem. How to 
define the relevant PHOSITA? In patent law the PHOSITA is a legal fictional character or a 
team of characters analogous to the “reasonable person” in the common law of torts. The 
PHOSITA is a statistical concept in the sense that there is a very high probability that no one 
from the community of ordinarily skilled persons in the relevant technical field(s) will be 
able to come up with the invention in question or its close equivalent or a superior one if the 
community was required to do so. So the PHOSITA, by definition, is neither a genius nor a 
layperson, but one possessing normal skills and knowledge in the required technical field. 
In this sense he serves as a litmus test for deciding if an invention is nonobvious or involves 
an inventive step. If the PHOSITA is deemed capable of coming up with the invention by 
applying his mind, knowledge, skill, and common sense, that particular invention is 
deemed unpatentable. In short, a “person of ordinary skill is also a person of ordinary 
creativity, not an automaton.”15  
Unfortunately, “ordinary skill” must be determined on a case-by-case basis, depending on 
the sophistication and technological features of the invention. Clearly, the ordinary skills of 
                                                 
14 Art. 54(2) EPC: “The state of the art shall be held to comprise everything made available to the public 
by means of a written or oral description, by use, or in any other way, before the date of filing of the 
European patent application.”  
15 KSR International Co. v. Teleflex Inc. et al, 550 U.S.__ (2007). Availlable at  
http://supreme.justia.com/us/550/04-1350/ 
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a nuclear physicist are different from those of a chef or a cobbler or a molecular biologist. 
Factors used in determining ordinary skill include the time frame of the invention; 
education level of the inventor, education level of active workers in the field of the 
invention, and the type of problems generally encountered in the field; prior art solutions 
relevant to the invention; rapidity with which innovations are made in the field; 
sophistication of the technology; etc. Further, with time, the profile of a PHOSITA, in 
advancing technologies, will only improve due to the infusion of new knowledge and skills. 
Therefore, in rapidly advancing fields, such as biotechnology, determining the profile of a 
PHOSITA requires great skill and frequent revision.   
The PHOSITA’s role is crucial in several places—in the enablement requirement, the 
nonobviousness requirement, the utility requirement (the invention must operate as 
described if he is to be enabled), and the written description requirement, as compliance 
with these requirements is measured from his perspective. Therefore, claims must be 
written so that a PHOSITA would understand the bounds of the patent, including the 
territory covered by the doctrine of equivalents. A fundamental test for the doctrine of 
equivalents is whether a PHOSITA would reasonably interchange the elements in a claim 
at issue in an infringement case. What is not clear is that as higher education spreads and 
the PHOSITAs learn to solve problems at conceptual levels, how that will affect the 
doctrine of equivalents. 
The enablement and non-obviousness questions arise before the issuance of a patent while 
the question of interchangeability arises at the time of infringement. Note that while 
biotechnology patent examiners are experts in biotechnology, infringement and validity 
cases are decided by judges who are not. So there is often a misalignment of the PHOSITA’s 
profile separately conjured by the examiner and the judge in any given biotechnology patent 
case. In fact, it is rather difficult for courts to insert, in their decisions, the role of “common 
sense” a PHOSITA might routinely employ in his day-to-day work. 
In infringement cases, the cut-off date chosen to ascertain prior art and the PHOSITA’s 
profile can become a critical factor even when the dates differ by only a few weeks. Scientific 
breakthroughs and pioneer inventions suddenly appearing on the scene around the cut-off 
date can complicate matters tremendously. In the fast changing world of biotechnology, 
what is nonobvious today may well be obvious next year or next week! 
5. Patentability conditions in biotechnology 
Large scale patenting of living matter is recent. Indeed, prior to 1980, few patents had been 
granted on non-living biological matter and biologically pure cultures of micro-organisms 
as they did not exist in nature in their pure form; they could only be produced in carefully 
controlled laboratory environments. Patent laws around the world till then had assumed 
that higher life forms were not patentable as they were deemed products of nature. An 
abrupt change in legal thinking occurred when the Supreme Court of the United States in its 
June 16, 1980 decision in Diamond v. Chakrabarty held that “a live, human-made micro-
organism is patentable subject matter” under the U.S. Patent Act of 1952. Recall that 
recombinant DNA technology was already well known in 1980. The Court reasoned that 
Chakrabarty’s microorganism was a “nonnaturally occurring manufacture or composition 
of matter—a product of human ingenuity” worthy of liberal encouragement under the 
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patent system. It declared that “the relevant distinction was not between living and 
inanimate things, but between products of nature, whether living or not, and human-made 
inventions.” The floodgates for biotechnology patents were thus opened in the United 
States,16 and eventually, using similar reasoning, patents on living matter were allowed in 
other countries. In 1988, the United States Patent and Trademark Office (USPTO) issued the 
first transgenic animal patent on the now famous Harvard mouse17, a mouse genetically 
engineered to be particularly susceptible to tumor growth. Patents have since been issued on 
many other genetically engineered plants and animals.  
The nature of biotechnology and its close working association with bioinformatics and 
molecular biology has added a new and complex dimension in patenting. The DNA is both 
a material molecule as well as a literal embodiment of coded information (the book of life). 
The courts are still trying to understand this deep two-facedness of DNA. For example, can 
artificially created DNA or gene sequences be copyrighted? 
Finally, when filing a biotechnology patent application, particular attention should be paid 
to meeting the legal requirements of (1) statutory subject matter, (2) utility, (3) novelty, (4) 
nonobviousness, and (5) specification (description, enablement, and claims). The vast 
majority of litigation cases revolve around these statutory requirements.  
5.1 Statutory subject matter 
Biotechnology deals with bio-matter itself (including products of biotechnology living or 
non-living) and processes of making bio-matter. Examples of non-living bio-matter are 
amino acids, peptides, proteins, fats and fatty acids, and nucleic acids. They are all chemical 
compounds and are usually better known in the form of antibodies, hormones, enzymes, 
antibiotics, steroids, cholesterol, DNA molecules, etc.  
The primary entity in living bio-matter is the cell, the smallest reproducible unit of life. A 
wide range of biotechnology product inventions, e.g., proteins, antibodies, intracellular 
components of plant and animal cells (DNA fragments, DNA constructs, DNA promoters, 
plasmids, vectors, RNAs, ribosomes, chloroplasts, mitochondria, Golgi bodies, etc.) and 
living matter per se, such as cell lines, fused cells, plant seeds, tissue cultures, 
microorganisms, plants and nonhuman animals, are patentable subject matter.  
Biotechnology process inventions include processes for sequencing DNA, RNA or proteins; 
processes for genetically manipulating cells, plants or animals; processes for recovering 
proteins produced by cell lines or animals; processes for detecting and characterizing 
mutagenic agents; processes for culturing tissue or cells; processes for diagnosing or 
detecting biological states; fermentation, chemical and diagnostics methods; methods of 
treating human or animal bodies; methods of controlling pests; etc. Biotechnology processes 
also provide the potential for creating genetically altered bio-matter itself. In the early to 
mid-1980s researchers were already creating genetically altered transgenic mice, hamsters, 
rats, hogs, poultry, cattle, sheep, and fish. In 2010, the first synthetic cell capable of 
                                                 
16 Chakrabarty was granted U.S. Patent No. 4,259,444, Microorganisms having multiple compatible 
degradative energy-generating plasmids and preparation thereof, filed on June 7, 1972, issued on March 
31, 1981. The patent has now expired. 
17 This was U.S. Patent No. 4,736,866, Transgenic non-human mammals, issued April 12, 1988 to Philip 
Leder and Timothy A. Stewart. The patent has now expired.  
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continuous self-replication was created, a cell that was completely controlled by a computer 
designed synthetic chromosome. 
5.2 The utility requirement (genetic materials) 
A patent examiner will accept a utility asserted by an applicant unless there is evidence or 
sound scientific reasoning against it. Clinical trials of a new pharmaceutical are not required 
to establish its utility18. Transgenic animals are generally created with a specific use in mind, 
so their utility is usually obvious. For gene sequences a nontrivial utility of the protein it will 
produce must be shown. Citing generic useful functions such as a marker, probe, or primer 
for various genetic researchers may likely be considered trivial given the present state-of-
the-art in gene research. 
New processes related to genetic materials must show utility for the product of a process as 
well as the process itself, otherwise one could end in patenting a process which yielded an 
unpatentable product. “Until the process claim has been reduced to production of a product 
shown to be useful, the metes and bounds of that monopoly are not capable of precise 
delineation. It may engross a vast, unknown, and perhaps unknowable area.”19 Less this 
constraint, the patentable field would be too broad. Therefore, to assert utility, say, for a 
process for making a protein, one must establish that the protein itself has substantial and 
specific utility in currently available form.   
General utility is disallowed because it would embrace a broad class of an invention. For 
example, regarding ESTs (expressed sequence tags), “a claim to a polynucleotide whose use 
is disclosed simply as a ‘gene probe’ or ‘chromosome marker’ would not be considered to be 
specific in the absence of a disclosure of a specific DNA target.”20 An EST does not explain 
the purpose and use of the gene. Therefore an EST patent “would amount to a hunting 
license”21 for performing research that may lead nowhere. Likewise, cDNA fragments used 
as probes for finding full-length genes lacks specific utility because, “[a]ny partial nucleic 
acid prepared from any cDNA may be used as a probe in the preparation and or 
identification of a full-length cDNA.” 22 Biotechnology patents must present a higher degree 
of utility than for most other types of patents, say, in mechanical or electrical engineering. 
5.3 The novelty requirement  
Non-naturally occurring life forms such as transgenic animals that are “man-made” or 
“man-altered” for the first time satisfy the novelty requirement. Gene sequences, either 
artificially created or purified and altered from their natural state, say, by deleting the 
introns and retaining the protein coding exons, may fulfill the novelty requirement. 
                                                 
18 See, e.g., In Re Brana, 51 F.3d 1560 (Fed. Cir. 1995). Available at 
http://law.justia.com/cases/federal/appellate-courts/F3/51/1560/618133/.     
19 Brenner v. Mansion, 383 U.S. 519 (1966). Available at 
http://supreme.justia.com/us/383/519/case.html.  
20 USPTO, Revised Interim Utility Guidelines Training Materials (1999) at 5. Available at  
http://www.uspto.gov/web/menu/utility.pdf.  
21 In re Fisher, 421 F.3d 1365, 1376-77 (Fed. Cir. 2005). Available at  
http://www.cafc.uscourts.gov/images/stories/opinions-orders/04-1465.pdf.  
22 USPTO, Revised Interim Utility Guidelines Training Materials (1999) at 51.  
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However, the current state-of-the-art in human gene sequencing and its rate of advance are 
such that in future litigation courts may well set a more stringent criterion for novelty. This 
is perhaps inevitable given that many of the products of interest to the biotechnology 
industry are synthetic versions of substances that already exist in nature, and creating those 
synthetic versions is within the capabilities of a PHOSITA. Under these circumstances, can a 
synthetic version be called “new”? While methods of use of “new” sequences may be novel, 
claiming those sequences as new compositions may not be easily allowed.23 
5.4 The nonobviousness requirement  
The nonobviousness requirement is an important policy lever by which governments can 
efficiently control the transfer of intellectual wealth to promote industrial products and 
processes. This is particularly important when dealing with innovative medical products 
and diagnostic tools being produced and mass marketed by multinational pharmaceutical 
and biotechnology firms. 
The core of a researcher’s activity is hypotheses testing. This is what many biotechnology 
PHOSITA do routinely. Scientific inventions in biotechnology rarely come about de novo. 
Thus how much of the experimental research or testing conducted in the lead-up to an 
invention is attributable to a PHOSITA is central to the obviousness test. Routine, ordinary, 
logical, or workshop activity is not deserving of patent monopoly. “The results of ordinary 
innovations are not the subject of exclusive rights under patent law;” otherwise “patents 
might stifle rather than promote the progress of useful arts.”24 Thus routine testing in the 
lead-up period to invention in anticipation of reasonable expectation of success should be 
expected of an ordinarily creative PHOSITA. 
Setting obviousness standards for gene patents is difficult because scientists use similar 
techniques to isolate different gene sequences, even though the gene may be new. A related 
question immediately arises. If homology-based utility satisfies the requirement of utility, 
would the invention be considered obvious? The USPTO’s view25, obviously in the context 
of U.S. patent law, is that nonobviousness and utility requirements are separate. This is 
because even though a claim to a nucleic acid is supported by a homology-based utility over 
a set of nucleic acids, that utility is not prima facie obvious. Homology-based deductions may 
provide a reason or motivation to make the claimed composition, but it would still be 
necessary to establish a fact-intensive comparison of the claim with the prior art rather than 
the mechanical application of one or another per se rule. In short, “obvious-to-try” and 
obviousness is not always the same thing (rules of thumb are not rules of law). The mere fact 
that something is “obvious to try” in view of known prior art does not automatically imply 
that the invention resulting therefrom is obvious. This is especially true where the prior art 
does not contain any suggestion or teaching that might suggest how the invention might be 
accomplished or any basis for reasonable expectation that beneficial results will accrue by 
proceeding along the lines taken by an inventor. 
                                                 
23 In re Gleave, 560 F.3d 1331 (Fed. Cir. 2009). Available at  
http://www.cafc.uscourts.gov/images/stories/opinions-orders/08-1453.pdf.  
24 KSR International Co. v. Teleflex Inc. et al, 550 U.S. __ (2007), at 24. 
25 Utility Examination Guidelines, USPTO, Federal Register, Vol. 66, No. 4, January 5, 2001, Notices, pp. 
1092-1099. Available at http://www.uspto.gov/web/offices/com/sol/notices/utilexmguide.pdf. 
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To assess nonobviousness requires profiling a PHOSITA, who in biotechnology usually 
holds a PhD and is therefore an expert in common perception. Moreover, this PHOSITA is 
more likely to be a team of experts rather than a “mythical individual”. So how does one 
reasonably determine this mythical PHOSITA at a point in time in an area of technology 
which is advancing so rapidly that the profile would need to be updated, at times, on a 
weekly basis? How are questions related to the doctrine of equivalents to be handled, 
especially if the invention is a synthetic version of a ‘product of nature’? After all, Nature 
too is experimenting constantly with its own creations, including the destruction and 
creation of new species in the predator-prey game of “survival of the fittest” or “natural 
selection”. These are extremely difficult questions to deal with in litigation.  
5.5 The specification requirement 
A specification is targeted at an expert in the field of the invention. Therefore, it is 
unnecessary for an applicant to spell out every detail but only enough to convince an expert 
that the inventor possessed the invention as of the filing date, and to enable a PHOSITA to 
make and use the invention without undue experimentation26. For example, in a gene 
related patent, a written description doesn’t need a recitation or incorporation by reference 
of genes and sequences that are well documented in the prior art. An adequate description 
of the invention therefore depends on the nature and scope of the invention, not the 
description’s length. Furthermore, an actual reduction to practice is not required. An 
invention can be “complete” even without an actual reduction. The Court of Appeals for the 
Federal Circuit in the United States, in Falkner v. Inglis, 448 F.3d 1357, 1366, 79 USPQ2d 1001, 
1007 (Fed. Cir. 2006)27 has succinctly stated: “(1) examples are not necessary to support the 
adequacy of a written description; (2) the written description standard may be met … even 
where actual reduction to practice of an invention is absent; and (3) there is no per se rule 
that an adequate written description of an invention that involves a biological macro-
molecule must contain a recitation of known structure.”  
Our current knowledge depicts living matter as incredibly complex (almost like a black-box) 
and therefore not describable either completely or accurately as required under the written 
description requirement. Inventions involving biological materials such as cell lines, cloning 
vectors, hybridomas, plasmids, microorganisms, etc., are sometimes impossible to describe 
adequately in words and reproducing them is not always a completely repeatable process. 
This problem is addressed by depositing appropriate biological materials with a recognized 
repository which provides permanence and availability to other researchers on demand 
(Berns, et al, 1996). This removes any uncertainty regarding the precise characterization of 
the material, such as a microorganism or cell line claimed in the invention, while ensuring 
that others will be able to practice the invention completely. In cases where the deposit 
requirement applies to higher-life forms, such as transgenic animals, the requirements may 
be satisfactorily fulfilled if a deposit of the lowest common denominator of a higher life 
form, e.g., the sperm, egg, fertilized egg, embryo, etc. is deposited. As on June 03, 2011, 75 
Contracting Parties had signed the Budapest Treaty on the International Recognition of the 
                                                 
26 If the profiled PHOSITA is generally expected to perform complex experimental tasks, then such tasks 
will not be considered as “undue”. 
27 Available at http://law.justia.com/cases/federal/appellate-courts/F3/448/1357/637048/.   
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Deposit of Micro-organisms for the Purposes of Patent Procedure28 (done at Budapest on 
April 28, 1977, and amended on September 26, 1980). The Treaty specifically requires the 
following: 
Contracting States which allow or require the deposit of microorganisms for the 
purposes of patent procedure shall recognize, for such purposes, the deposit of a 
microorganism with any international depositary authority. Such recognition shall 
include the recognition of the fact and date of the deposit as indicated by the 
international depositary authority as well as the recognition of the fact that what is 
furnished as a sample is a sample of the deposited microorganism. (Article 3(1)(a)) 
As far as matters regulated in this Treaty and the Regulations are concerned, no 
Contracting State may require compliance with requirements different from or 
additional to those which are provided in this Treaty and the Regulations. (Article 3(2)) 
The satisfaction of the specification requirement is largely a procedural matter and depends 
on the skill of the patent counsel and the inventor’s cooperation in preparing the patent 
application. On the other hand, fulfilling the requirements of utility, novelty, and non-
obviousness depend more on the substantive merits of the invention itself.  
6. Patent related treaties & agreements 
Grant of patents and their enforcement, if infringed, rests with national governments. 
Differing national economic and geopolitical needs have resulted in wide differences among 
national patent systems that, at times, have led to odious disharmonies in patent 
enforcement and flow of trade and commerce. There has been a long-felt need for 
harmonized patent laws, especially by those who need their inventions protected 
concurrently in major world markets. Since the 1880s, limited harmonization among groups 
of nations, mainly related to procedural matters, has been achieved through various 
international treaties. The important ones are: (1) Paris Convention for the Protection of 
Industrial Property (1883),29 (2) Patent Cooperation Treaty (1970),30 (3) Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS) (The Agreement is Annex 1C of the 
Marrakesh Agreement Establishing the World Trade Organization, signed in Marrakesh, 
Morocco on 15 April 1994),31 and (4) The Trilateral Cooperation (1983)32 agreement among 
the patent offices of the United States, Europe, and Japan.  
6.1 The Paris Convention 
The Paris Convention (1883), now administered by the World Intellectual Property 
Organization (WIPO)33, has shaped the patent laws of various countries, especially those of 
its member States called Contracting Parties. It was the first important international treaty 
designed to help people of one country obtain protection in another for their intellectual 
                                                 
28 Available at http://www.wipo.int/treaties/en/registration/budapest.  
29 Available at http://www.wipo.int/treaties/en/ip/paris/trtdocs_wo020.html.  
30 Available at  http://www.wipo.int/pct/en/texts/pdf/pct.pdf.    
31 Available at http://www.wto.org/english/docs_e/legal_e/27-trips.pdf.  
32 Website: http://www.trilateral.net/index.html.  
33 WIPO “is responsible for the promotion of the protection of intellectual property throughout the 
world through cooperation among States”. Website: http://www.wipo.int//portal/index.html.en. 
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creations in the form of inventions (patents), trademarks, and industrial designs. As on July 
15, 2011, there were 173 member States34. The Convention does not allow Contracting 
Parties to discriminate between their own nationals and nationals of other Contracting 
Parties as regards the protection of industrial property. Inter alia, the Convention lays down 
the common basic structure for patent protection to which the Contracting Parties are 
bound. This basic structure does not unduly trespass on the sovereign rights of Contracting 
Parties or compromise their national interests. In fact, Article 19, of the Convention states 
that Contracting Parties “reserve the right to make separately between themselves special 
agreements for the protection of industrial property, in so far as these agreements do not 
contravene the provisions of this Convention.” Because of this, patent laws of respective 
member States share a substantial common core. 
The Paris Convention forms the foundation for two other important treaties related to 
patents—the Patent Cooperation Treaty (1970) and the Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS) (1995). 
6.2 Patent Cooperation Treaty (PCT) 
The Patent Cooperation Treaty (PCT), administered by WIPO, became operational on June 1, 
1978. As of September 23, 2011, the PCT had 144 signatories35. While the Paris Convention 
provides a means of access into different countries’ patent systems, a patent application 
once filed, must be prosecuted through each national patent system. Under the PCT, patent 
applicants from Contracting States enjoy a relatively simple way of commencing patent 
applications in a number of countries simultaneously. This provision has since been 
encoded in the patent laws of most Contracting States.  
The PCT provides a centralized mechanism for filing patent applications, prior art search 
and preliminary examination of the patent application; it does not grant patents. PCT 
Contracting States are bound by Chapter II of the PCT relating to the international 
preliminary examination of patent applications. An applicant can designate specific 
countries or regional conventions for grant of patent by filing an international patent 
application in the appropriate receiving office. After an international search report and a 
non-binding preliminary opinion on patentability has been provided, the applicant must 
still apply separately and individually to each jurisdiction where patent protection is 
required. While the search and the preliminary opinion might reduce subsequent search-
related workload of national patent offices examining the patent application, the main and 
substantial workload still belongs to the national patent office. Every biotechnologist should 
become familiar with the process of filing a patent application under the PCT. 
6.3 TRIPS 
Of all the treaties in force, TRIPS is the most ambitious. Ratification of TRIPS is a 
prerequisite for a country to become a member of the World Trade Organization (WTO)36. 
As on October 4, 2011, WTO had 153 members. TRIPS entered into force on January 1, 1996, 
and covers various forms of intellectual property rights, including patents. It introduced 
                                                 
34 Visit http://www.wipo.int/export/sites/www/treaties/en/documents/pdf/paris.pdf for updates.   
35 Visit http://www.wipo.int/pct/guide/en/gdvol1/annexes/annexa/ax_a.pdf for updates.  
36 Web site: http://www.wto.org/.   
www.intechopen.com
 
Innovations in Biotechnology 
 
366 
intellectual property law into the international trading system for the first time. It was 
negotiated at the end of the Uruguay Round of the General Agreement on Tariffs and Trade 
(GATT) in 1994. TRIPS nudged signatory countries towards a level of uniformity, which most 
are still struggling to cope with even though it was sweetened with some concessions for 
developing and underdeveloped countries. For example, art. 1.1 leaves member states “free to 
determine the appropriate method of implementing the provisions of this Agreement within 
their own legal system and practice” and a November 2005 decision of the Council for TRIPS 
allowed least-developed country members to postpone implementation of many TRIPS 
obligations until 2013.37 The difficulties faced by developing countries are not just due to their 
inferior stages of technological advancement but also due to social, administrative, 
infrastructural, and other costs incurred in implementing TRIPS. This is particularly visible in 
the case of pharmaceutical products.38  
Under the TRIPS Agreement, member countries are required to make patents available “for 
any invention, whether products or processes, in all fields of technology” without 
discrimination, subject to certain legal requirements being met. These requirements are that 
they must fulfill the member country’s legislated criteria for novelty, inventiveness, and 
industrial applicability. Further, once patent rights are granted, the owner of the patent 
should be able to enjoy those rights in the member country without discrimination as to the 
place of invention and whether products are imported or locally produced. The above is 
subject to three exceptions: (1) the invention should not be contrary to ordre public or 
morality; (2) inventions related to diagnostic, therapeutic and surgical methods for the 
treatment of humans or animals may be excluded from being patented; and (3) inventions 
related to plants and animals other than micro-organisms and essentially biological 
processes for the production of plants or animals other than non-biological and 
microbiological processes may be excluded. However, when such exclusions are made in 
the patent system for plant varieties, an effective sui generis system of protection must be 
provided. Subsequent to the Doha Round which took several years to negotiate, TRIPS 
permits countries to issue compulsory licenses to meet the health needs of nations unable to 
produce locally needed medicines.39 This, however, means little to countries which lack the 
ability to manufacture pharmaceuticals locally. 
Several TRIPS articles remain open to wide interpretation to allow each member country 
freedom to tailor its patent system according to its domestic needs, present state of 
development, and growth potential. For example, while TRIPS lists an “inventive step” as 
one of the requirements for patentable subject matter (art. 27(1)), it does not define the term. 
Likewise it defines the scope of a patent in terms of the nature of the rights conferred (art. 
28), but does not set out the breadth of the technological terrain a patent must cover. This 
allows member states to supply their own definitions of “inventive step” and determine the 
scope of patent protection.  
                                                 
37 For developing countries, the patent standards (articles 27-34) of the TRIPS Agreement became 
generally operational on January 1, 2000. Those developing countries that did not allow product patents 
on pharmaceutical and agricultural chemical products were given a grace period of five years to cover 
them, subject to a “mail box” provision for patents arising in the meantime.  
38 See, e.g., Janice M. Mueller, Taking TRIPS to India—Novartis, Patent Law, and Access to Medicines, 356 
New England Journal of Medicine, 541, 541 (2007).    
39 Declaration on the TRIPS Agreement and Public Health (adopted on November 14, 2001). Available at 
http://docsonline.wto.org/DDFDocuments/t/WT/Min01/DEC2.doc.   
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6.4 The Trilateral Cooperation 
The Trilateral Cooperation was set up in 1983 between the USPTO, the European Patent 
Office and the Japan Patent Office (collectively known as the Trilateral Offices) to overcome 
certain problems arising due to a dramatic rise in the number of patent filings in the early 
1980s. These Offices process the greater part of all patent applications filed worldwide 
including PCT applications. Under the Cooperation, the Offices focus on addressing global 
patent workload challenges, e.g., decreasing pendency and examination backlogs, 
improving patent quality, and leveraging IT solutions to accelerate processing of patent 
applications. Through work sharing arrangements the Offices leverage work done earlier by 
another Office to improve their own search and examination practices. One of their goals is 
to eventually develop a paperless administration of the patent procedure, the exchange of 
documents, and electronic filing of applications. 
6.5 Hurdles in the path of harmonization 
Attempts to harmonize different national patent systems face major hurdles: the standards 
to be followed for utility, novelty, and nonobviousness; defining circumstances when 
research exemption and compulsory licensing are appropriate; setting objective standards 
for analyzing infringement and award of relief; etc. These issues are dealt with in widely 
differing ways by different countries. Any debate on global harmonization must also 
consider alternative mechanisms for encouraging technological innovation, not just the 
patent system, and account for the fact that different countries are at different stages of 
transition—from the industrial age to the information age. A recent paper (Reichman and 
Dreyfuss, 2007) succinctly notes: 
[T]he worldwide intellectual property system has entered a brave new scientific epoch, 
in which experts have only tentative, divergent ideas about how best to treat a daunting 
array of emerging new technologies. The existing system has become increasingly 
dysfunctional because it operates with a set of rudimentary working hypothesis that 
have not kept pace with technical change. 
Any attempt to push harmonization beyond TRIPS would require great care. At the least, 
individual nations must be clear about the patent system that would best serve their 
interests in the new knowledge economy. The daunting nature of the task becomes 
evident from the experience of the United States, which after six years of feet-dragging 
and several aborted attempts at reforming its Patent Act, finally enacted the Leahy-Smith 
America Invents Act, 201140 on September 16, 2011. It is seen as “a jobs creation bill.” The 
Act, most importantly, changes the earlier “first-to-invent” system to a “first-to-file” 
system to make it compatible with the rest of the world, raises patentability standards, 
makes injunctions and damages harder to obtain, provides new options for challenging 
bad patents, provides enhanced funding of PTO operations, provides for expedited 
examination of patent applications (for a fee), etc. Full implementation of the new law will 
take several months. A lack of political will to sink differences to bring about change was 
evident throughout.  
                                                 
40 Available at  
http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=112_cong_bills&docid=f:s23es.txt.pdf.  
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7. Societal impact of biotechnology patents 
Since the 1970s the spotlight has shifted from technological advances of the industrial 
revolution (driven by Newton’s laws of motion and Maxwell’s laws of electromagnetism) to 
advances in biotechnology (driven by molecular biology and biochemistry). Towards the 
end of the twentieth century, conventional wisdom asserted that while that century 
belonged to physics and chemistry, which led to huge industrialization and consequent 
megacities, the twenty-first century will belong to biology and associated technologies. Its 
impact on society is expected to be phenomenal, affecting every inhabitant on our planet in 
an intimate way. The nature of the impact will crucially depend on how society accepts or 
rejects new technical innovations in biotechnology (Smith, 2009). Even though, since the 
1980s, biotechnology has been recognized and welcomed as a highly promising strategic 
technology by many industrialized nations (Bera, 2009c), it has not resulted in automatic 
acceptance by society. The rate at which R&D results can be assimilated will depend less on 
scientific or technical considerations but more on such factors as availability of venture 
capital, the ability to acquire and protect patents, marketing skills, the efficacy and cost-
effectiveness of new technologies, and possibly of far greater importance, public perception 
and acceptance. Perhaps no other industry is as heavily dependent on patents as the 
biotechnology industry and on public trust. 
The emergence of the modern biotechnology industry in the 1970s as an intermediate sector 
between academic research institutions and Big Pharma was novel. Academic researchers 
played an important role in the founding of many biotechnology companies; some 
participated in both worlds, some turned into entrepreneurs. University-industry 
collaboration became a critical factor in commercial success as did the foresight of some 
venture capitalists who were willing and able to support inexperienced companies entering 
a market with a seven- to ten-year product development cycle. Indeed, without patent rights 
in areas such as isolation and purification of proteins, DNA sequences, monoclonal 
antibodies, transgenic organisms and gene expression systems, etc., many biotechnology 
companies could not exist (Bera, 2009b; Williams, 2005).  
7.1 New technologies spark patenting debates 
Historically, the birth of each new technology tends to spark a patenting debate. In the early 
20th century the debate was whether agricultural inventions could be patented on the 
grounds that agriculture was not an industry. In the 1970s, it was argued that 
pharmaceutical patents were unethical. In the 1980s, the biotechnology industry faced 
hostility over “patenting of life”. Even now, bioethical, social, and legal questions related to 
biotechnology patents are far from being over, as are issues related to intellectual property, 
scientific integrity, and conflicts of interest in research. For a satisfactory resolution, the 
debate must involve experts from diverse fields: science, engineering, theology, and 
philosophy. Finally, since the 1990s, the computer revolution and the Internet have 
produced many controversies related to software and business method patents (Poynder, 
2000). An apparently persuasive argument against biotechnology patents is the field’s rapid 
pace of development. For example, a few decades ago, finding a gene may have taken ten 
years, but now one can be found within seconds using a computer search and gene maps 
(Demaine & Fellmeth, 2002). If invention is inevitable, does it merit reward of exclusivity? If 
yes, for how long? A long period may spur innovation but also limit the spread of new and 
useful products and processes and make them more expensive. On the other hand, rapid 
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discovery of genes does not imply rapid availability of useful and safe applications based on 
those genes. Those applications come from creative geniuses. Should they not be rewarded 
with patents? For inventions, such as vaccines for public health, the balancing act is never easy, 
given the enormous R&D costs of developing them and the crucial role of Nobel class 
researchers who make them possible. As Todd Dickinson (former director of the USPTO) once 
remarked, “there are so many chemicals in the human body that, if we ruled them all off limits 
to patenting, we would rule out an extraordinary number of valuable and important 
inventions. … Without the funding and incentives that are provided by the patent system, 
research into the basis of genetic diseases and the development of tools for the diagnosis and 
treatment of such diseases would be significantly curtailed.” (Dickinson, 2000) 
Another objection is that the “current model rewards particular kinds of creative effort, 
namely those which result in commercial gain. It is therefore likely to hinder innovation of 
products that have limited market value, but which have huge social benefit.”41 This flawed 
argument overlooks the obvious fact that intellectual property laws were meant to encourage 
commercial gain. There are other laws which encourage social benefit and one does not 
criticize those laws for hindering innovation that lead to commercial gains. The correct 
approach, if providing social benefit which have limited market value is the objective, is to 
elect governments that will act more enthusiastically in providing social benefits (of course, 
the government will have to increase taxes to do so), encourage the general population to 
contribute to philanthropic activity by donating time and service to community activities, 
including creating intellectual property. There are no laws against such philanthropic 
activities, but there is a huge lack of enthusiasm on the part of the general population to 
help itself. That same population works more energetically when it gets a share of 
“commercial gains” in terms of employment opportunities and wages. Commenting on the 
allegation that the global intellectual property regime denies poor people access to drugs, 
Alasdair Poore said, “Without an effective patent system, who would have made the 
necessary investment to discover and manufacture those drugs? It’s politics and economics 
that block access to drugs for the world’s poor, not the IP system.” (Prowse, 2009) 
On closer inspection, one finds that the broadest debates concern ethical and societal aspects 
of patenting genetic materials, the perceived rights of indigenous communities that have 
shaped their environment and its organisms and thus the genetic resource embodied 
therein, and the manner in which the bioindustry prospects (or allegedly pirates) biological 
resources of poor countries and commercializes the products it derives through patents 
(Koopman, 2003). At another level, while patenting of biotechnology inventions is being 
criticized, it is really the science behind it that the opponents seem to be against. 
7.2 Knowledge is commercial power 
An important, although not the only, measure of a technology’s success is its embodiment in 
products and processes that generate a profitable commercial market through public 
acceptance. Public acceptance is a factor only if there is a supplier willing to assume business 
risks and enter the market. One might then assume that if a suite of patentable products and 
                                                 
41 See, e.g., Who Owns Science? The Manchester Manifesto, Institute for Science, Ethics and Innovation, 
The University of Manchester, 2009. Available at  
http://www.isei.manchester.ac.uk/TheManchesterManifesto.pdf.   
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processes, paid for out of the public purse, were owned by the government and made 
available free or at a nominal cost for commercial exploitation, business risks would be 
lowered. That such is not the case was the genesis of the Bayh-Dole Act42 of 1980 in the 
United States. What the government found was that discoveries made in the universities 
with federal funds were grossly underutilized43 because government policy required that it 
take title to all such inventions and license them non-exclusively. The vast majority of 
university discoveries, as expected, were early stage discoveries that required substantial 
additional investment to turn them into a marketable product. It was estimated in 2002 that 
a “dollar’s worth of academic invention or discovery require[d] upwards of $10,000 of 
private capital to bring to market.”44 (The government funds the ‘inspiration’ while the 
private sector funds the ‘perspiration’!) “New drug development costs have risen from $0.8 
billion (1997) to an expected $1.9 billion (2013).”45 Without the protection of an exclusive 
license, companies were reluctant to invest huge sums when the resulting products could 
easily be appropriated by competitors.46 
The Bayh-Dole Act was a bold, against-the-grain, initiative meant to rejuvenate the U.S. 
economy. Under Bayh-Dole, the government relinquished its intellectual property rights on 
the outputs of federally funded research and permitted universities and small businesses to 
acquire title to inventions created with federal funds. It also allowed exclusive licensing of 
patents thus acquired, to industry since, without it, companies were wary of investing in the 
further development of university developed technologies. In addition, descriptions of 
inventions were given legal protection from public dissemination and from requests under 
the Freedom of Information Act47 for a reasonable period to enable patent applications to be 
filed. In return, the government retained a royalty-free, non-exclusive license to practice the 
patented inventions coming out of federally funded research throughout the world 
(including use by government contractors) and held ‘march-in rights’, which allowed the 
government to take back the title if the patent owner failed to commercialize the invention. 
However, the exercise of march-in rights was made substantially difficult and appealable in 
courts. The march-in rights were basically introduced to prevent companies from licensing 
university patents with the sole intention of blocking rival companies from doing so. The 
                                                 
42 University and Small Business Patent Procedure Act of 1980, (Pub. L. 96-517), §6(a), Dec. 12, 1980, 94 
Stat. 3018 (35 U.S.C. 200 et seq.). Also known as the Bayh-Dole Act of 1980, it was given effect from July 
1, 1981, “to use the patent system to promote the utilization of inventions arising from federally funded 
research or development.”   
43 In 1980, the Federal Government held title to approximately 28,000 patents. Fewer than 5% of these 
were licensed to industry for development of commercial products. (See The Bayh-Dole Act: A Guide to 
the Law and Implementing Regulations, Council on Governmental Relations, October 1999, p. 2. 
Available at  
http://www.cogr.edu/docs/Bayh_Dole.pdf.)  
44 Innovation’s golden goose, The Economist, December 14, 2002, p. 3. 
45 Wai Lang Chu, CRO’s drug R&D contribution never been more significant, 25 September 2006. 
Available at http://www.outsourcing-pharma.com/Preclinical-Research/CRO-s-drug-R-D-
contribution-never-been-more-significant.  
46 The Bayh-Dole Act: Important to our Past, Vital to our Future, 2006. Sense of Congress resolution 
passed by the U.S. House of Representatives on December 6, 2006. Available at 
http://www.autm.net/Content/NavigationMenu/About/PublicPolicy/BDTalkPts031407.pdf. 
47 Available at http://usgovinfo.about.com/library/foia/blfoiacode.htm.   
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rights were meant to ensure fair competition and to meet the needs of U.S. citizens; they 
were not meant for the government to set prices, as some have tried to claim.48  
So, post-Bayh-Dole, we now witness the hitherto unimagined situation where innovations, 
already paid for by the public, can be brought to the market only if those innovations are 
privatized and resold to the public via patents acquired by commercial entities. Otherwise 
certain markets will likely vanish on their own because the risks are too high! The 
biotechnology industry, through university-industry collaboration, has shown that 
knowledge is a phenomenal commercial power. The emulation of the Act by other 
countries, although common now, will not necessarily have the same impact that has been 
visible in the U.S. because of dissimilar national circumstances, or the absence of world-class 
research universities.  
Patent laws never anticipated that together “blue sky” research and living matter would 
play such a fundamental role in late 20th century commerce with such speed, and 
economists and policy makers never imagined the deep post-1980 university-industry (or 
generally, public-private) collaborations that rapidly gained momentum in the 
biotechnology sector following three signal events in 1980 in the United States: the Bayh-
Dole Act, grant of the Cohen-Boyer patent, and the Chakrabarty court decision (Bera, 
2009d). These rapid changes have bewildered lawmakers, patent offices, the judiciary, and 
relevant enforcement agencies. To older generations it is sacrilege that “even the pure quest 
for knowledge is subverted by the need for profit.”49 To the new generation it is the 
welcome emergence of a new and refreshing paradigm where pure knowledge is rapidly 
converted to applications to serve consumers through conventional market mechanisms of 
demand and supply. The future may see the emergence of other market mechanisms, whose 
advent no economist will likely anticipate, because they will occur to accommodate needs 
triggered by innovation alongside need inspired innovations.   
The writing on the wall is clear; the times are changing, and so must the way we teach, create, 
use, and protect knowledge and the innovations they spawn. Initially, important chunks of 
that knowledge in biotechnology coming from universities will be tacit and scarce, hence 
university-industry collaboration will be crucial for technology transfer and commercial 
success. The relative youth of the biotechnology industry and its dependence on scientific 
breakthroughs means that star scientists—their accessibility, location, motivation to collaborate 
at the bench-science level with scientists in industry in converting basic scientific knowledge 
into commercially viable products and processes—will be crucial in determining the pace of 
diffusion of tacit scientific knowledge (Zucker & Darby, 1996). To remain relevant in an 
economically global world, the social role of universities and government research laboratories 
must change as must our understanding of morality, ethics, and citizenship.  
It is mainly due to the university-industry collaboration example set by the United States 
that universities elsewhere are now expected to transform themselves into engines of 
economic growth, rather than remain as not-for-profit ivory towers. This is an enormous 
social transformation, and an enormous opportunity for universities to help the world settle 
down in the new era of a knowledge-intensive global economy. In this world, university-
                                                 
48 Statement of Senator Birch Bayh to the National Institute’s of Health, May 25, 2004. Available at 
http://www.ott.nih.gov/policy/meeting/Senator-Birch-Bayh.pdf.   
49 The quote is from John Sulston, How science is shackled by intellectual property, The Guardian, 26 
November 2009.  
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industry collaborative research is a natural means of providing continuing education to 
knowledge workers throughout their professionally productive life. It is also a natural 
means of mutual technology transfers between academic researchers and applied industry 
researchers, especially of tacit knowledge. Donald Kennedy of Stanford University was spot 
on when he said, “Technology transfer is the movement of ideas in people.”50 This 
movement in biotechnology must frequently happen under the protective cover of patents. 
One of the outstanding examples of technology transfer between university and industry is 
the licensing policy adopted by Stanford University with respect to the Cohen-Boyer 
patents51 (Bera, 2009a). No doubt, other technology transfer models to fulfill emerging needs 
will evolve as the biotechnology sector matures. 
Modern science-based industries (SBIs) critically depend on monetary funds, star scientists 
(human capital), and protected intellectual property (intellectual capital). Where and when 
star scientists publish also has a determining effect on the commercial adoption of new 
technologies. Geographically, SBIs tend to nucleate in close proximity of universities hosting 
a star group of scientists active in the relevant science, as it greatly improves mutual 
accessibility of both people and research facilities. This has generally been the case for 
biotechnology, especially in the United States (Zucker & Darby, 1996). Governments must 
bear this in mind when framing policies for economic and industrial growth and providing 
infrastructure. Once nucleation is complete and substantial diffusion of tacit knowledge of 
the stars has taken place, further expansion of the industry can spread to far-off places, 
especially of manufacturing units and support R&D groups.  
7.3 Gene patents (unresolved issues)  
A recent gene patent case, Association for Molecular Pathology v. the USPTO and Myriad 
Genetics, No. 10-1406 (Fed. Cir. 2011)52, decided by the United States Court of Appeals for 
the Federal Circuit, has gained extraordinary attention. In this case, the validity of a series of 
patents that claim isolated DNA compositions and methods for testing the presence of 
genetic mutations that are correlated with an increased risk of certain breast and ovarian 
cancers (the BRCA1 and BRCA2 genes) was challenged. Myriad owns or is the exclusive 
licensee of these patents. Opponents of the patents argued that the patent claims encompass 
patent-ineligible subject matter, e.g., products of nature. At issue were such fundamental 
questions as to whether isolated DNA should be eligible for a patent, and whether the 
patenting of genes promotes or stifles innovation and development of new diagnostics and 
therapies.  The Court stated expressly that an isolated partial DNA fragment, not just cDNA 
has a “markedly different structure to native DNA” and so reaffirmed that isolated gene 
sequences are patentable. Patentability of DNA sequences as diagnostics remains uncertain. 
Whether the Supreme Court of the United States will entertain an appeal in the Myriad case 
is not yet known. 
Quite independent of how this case eventually ends, patent law will need to revisit the grant 
of gene patents. We now know that the one-gene-one-protein assumption of yore is no 
                                                 
50 As quoted in Zucker & Darby, 1996.  
51 Stanford University, which owned the patents, granted non-exclusive licenses to 467 companies and 
amassed licensing revenues of $255 million. The patents expired in 1997. 
52 Available at http://www.cafc.uscourts.gov/images/stories/opinions-orders/10-1406.pdf.  
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longer true. The proteome is larger than the genome—there are more proteins than genes due 
to alternative splicing of genes and post-translation modifications like glycosylation and 
phosphorylation. The cause of most disorders and diseases is a combination of genetic and 
environmental factors and this raises important questions about the adequacy, scope and 
purpose of patent law in view of rapidly advancing knowledge in biotechnology and related 
fields. It is amply possible that under present laws, a single gene or a short DNA sequence, if 
patented, could result in a near monopoly on diagnostic tests and treatments for widespread 
and serious ailments, such as, diabetes, cancer, multiple sclerosis, and Alzheimer’s disease. 
Can such patents be considered as serving human society if the patent owner cannot pursue 
all known downstream opportunities and blocks others from pursuing those or new ones? If 
such patents are inevitable, what steps should be taken to ensure that they do not obstruct 
others ready to pursue opportunities not pursued by the patent owner. Even otherwise, courts 
and administrative agencies continue to struggle with issues raised by gene patents and their 
predecessors—chemical patents—as to when and how patents should be granted on 
biochemicals in their natural and modified states under existing patent laws.  
The fact that creation of transgenic humans is, in principle, possible, inevitably raises 
questions of human dignity, and moral and ethical issues. There appears to be a general 
consensus that transgenic humans are not patentable. Yet, no unambiguous definition of a 
transgenic human exists. Given that the genomic DNA differences between human and 
chimpanzee is only about 1.2%, the possibility of creating a patentable transgenic talking 
chimpanzee that can communicate with humans is not a fantasy. Such a chimpanzee might 
actually be able to speak and be capable of making connections between human words, 
objects, and even emotions. For the first time we may then be able to establish verbal 
communication with another species and derive remarkable insights about the animal 
kingdom. Should this possibility be denied to the human race because the transgenic 
chimpanzee is also a transgenic human? (Bera, 2009d) 
The owner of a gene patent does not “own” any organism containing that gene. Thus, a 
person whose body contained a patented gene would not infringe the patent. However, if a 
gene, patented or not, is inserted into a living organism that organism may become 
patentable and then commercially exploited. Ownership and commercial exploitation of 
plants and animals, such as buying and selling them, is widely accepted in our society, but 
not of humans in today’s world. Finally, animal breeding is not new and has been practiced 
since virtually the beginning of agriculture. Human breeding through marriage customs is 
also not new. Clearly, when one discusses moral issues related to patents, it is not the 
invention that is morally repugnant but its use in certain unintended ways. No one in the 
patent system—inventors, patent examiners, judges, or even legislatures (representing the 
people) can anticipate all uses of a particular patent that may eventually turn out to be, on a 
statistical balance, detrimental or beneficial to society. Any premeditated restrictions on the 
grant of patents must carefully consider the possibility that such restrictions may undermine 
the patent law’s primary objective of promoting technical innovation.  
8. Concerns over biopiracy 
A paradigm shift inevitably entails shifts of power. The rise of biotechnology has sharpened 
the divide between the science-based industrial nations, and the genetically endowed but 
less-developed nations whose genetic resources are prospected by the former. The 
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conflicting issues being debated include the proprietary character of natural genetic material 
and the nature of commercial exploitation of the value added to those materials through 
R&D. Natural genetic resources abound in developing countries with a tropical climate, e.g., 
Brazil, Peru, Costa Rica, and India, in the form of gene pools, organisms, and ecosystems. 
Biotechnologists are obviously interested in these resources and related ‘traditional 
knowledge’ held by indigenous communities as inputs to research while the biotechnology 
industry is interested in prospecting those resources for potential commercial exploitation.  
The methodology and approach of traditional knowledge is holistic and applied according 
to notions of biocentricism (a political or ethical stance which asserts the value of non-
human life in nature), co-evolution and equality; it does not rely on empirical verification, 
rather it seeks connections between the physiological characteristics of organisms (visible 
phenotypic properties) with their spiritual ones. In contrast, modern biotechnology 
concentrates on biochemical genotypic properties. Nevertheless, traditional knowledge can 
be a valuable starting point for biotechnologists by indicating to them specific organisms 
and their known medical usage (Koopman, 2003). The enormous gap in terms of 
effectiveness and use between products and processes derived from traditional knowledge 
and from modern biotechnology must be filled by very expensive R&D, which is clearly 
outside the capabilities of indigenous communities. These are uncontested facts.  
The biopiracy debate then essentially revolves around ethical and societal values as viewed 
from two widely different cultures over the patenting of genetic material whose natural 
inputs were prospected in and transported from indigenous communities on the basis of 
their traditional knowledge, with next to nothing in return in terms of acknowledgement or 
affordable products and processes or sharing of R&D knowledge. In short, the indigenous 
communities see this as blatant biopiracy. This is a clash between two cultures—of shared 
community rights against privately held individual rights. Indigenous communities seldom 
recognize the concepts of individual ownership, exclusion and competition that underlie the 
Western concepts of property law regimes. 
Such irreconcilable differences have found palatable compromises in the form of the 
Convention on Biological Diversity53 and TRIPS, where each culture makes concessions to 
the other. Countries providing access to genetic resources or traditional knowledge are 
permitted, and some have implemented, sui generis systems where they provide access on 
certain conditions, such as, getting prior informed consent of a national office dealing with 
such matters, benefit sharing arrangements (e.g., sharing of proceeds derived from 
commercial exploitation, training in R&D, transfer of technology under ‘fair and most 
favorable terms’ consistent with the ‘adequate and effective protection of intellectual 
property rights’), and treating certain violations of the statutes as criminal offenses, in 
exchange for biological samples and traditional knowledge. In a subtle way, these sui generis 
systems are enforcing “reach through claims” on others for advantages nature has endowed 
indigenous communities with and the traditional knowledge they have developed long ago. 
The debate never mentions the tremendous unpatentable scientific knowledge of Newton, 
Maxwell, Einstein, and others which has been freely bestowed on the world without seeking 
rents, and which has allowed such dreams as putting a man on the moon possible. 
                                                 
53 Available at http://www.cbd.int/doc/legal/cbd-en.pdf.  
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9. Conclusions 
Our new understanding of living matter is leading us to uncharted territories. Recombinant 
DNA technology, transgenic animals, synthetic cells are just the tip of the iceberg. Creation 
of computer designed, engineered life is no longer science fiction but a potential reality. Will 
surreptitiously created transgenic humans one day enslave natural humans and rule the 
world. Can such an event be stalled? What will a world dominated by transgenic humans be 
like? Will it be more humane than ours? Will they rule more by the head and less by the 
heart or the other way round? We have no way of knowing. 
While patent laws forbid patenting of abstract ideas, thought processes, laws of nature, 
natural phenomena, and products of nature so as not to stifle advancement of knowledge, 
the laws do recognize, as they did for Galileo, that certain down-to-earth inventions, 
conjured through human ingenuity by applying these forbidden things, go beyond 
philosophical musings and have potential commercial value, because of their utility to 
humans. In such cases, a quid pro quo system that provides limited period monopoly with 
commercial advantage in the form of patents, in exchange for a full public disclosure of the 
invention not later than the date of patent grant, encourages further creation of new 
inventions or improvements over old ones. Patent laws were meant to encourage 
commercial gain in an equitable manner. There are other laws and practices that encourage 
material and spiritual contributions to society through raised taxes, philanthropy, free social 
service, open-source, etc., which are not motivated by commercial gain. Patent laws do not 
interfere with these other laws and practices. Outside of contractual obligations to, say, his 
employer, a biotechnologist can choose to patent or not patent. Patent laws do not operate in 
isolation. Their purpose is to benefit society on the whole so that the positives outweigh the 
negatives in a statistical sense. There is no denying that countries with a thriving patent 
system, with all its faults, have advanced technologically more rapidly than all other 
countries and provided a better quality of life to their citizens. It is hoped that this chapter 
will help the reader decide when patenting is appropriate in light of other alternatives. 
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